In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Incyte (INCY – Research Report). The company’s shares opened today at $52.00.
According to TipRanks, Bratzel is a 2-star analyst with an average return of 0.1% and a 40.91% success rate. Bratzel covers the Healthcare sector, focusing on stocks such as Incyte, Ionis Pharmaceuticals, and Akebia Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $73.20 average price target.
INCY market cap is currently $11.66B and has a P/E ratio of 19.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte (INCY) Company Description:
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More on INCY:
